Eli Lilly (NYSE: LLY) shares are trading higher on Monday amid overall strength in the health care sector.
The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
Eli Lilly shares were trading up 2.46% to $157.24 at time of publication on Monday. The stock has a 52-week high of $164.90 and a 52-week low of $101.36.